by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION This study aims to investigate the relationship between blood-based pathologies and established risk factors for cognitive decline in the community-based population of Chongqing, a region with significant aging. METHODS A total of 26,554...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION The availability of amyloid beta (Aβ) targeting therapies for Alzheimer’s disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation. METHODS We evaluated fully-automated Lumipulse...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) co-pathology with Lewy bodies (LB) is frequent and influences clinical manifestations and outcomes. Its significance in primary age-related tauopathy (PART) is unknown. We investigated the influence of LB on...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION The effects of sex and apolipoprotein E (APOE)—Alzheimer’s disease (AD) risk factors—on white matter microstructure are not well characterized. METHODS Diffusion magnetic resonance imaging data from nine well-established longitudinal...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in...
